BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. Semin Arthritis Rheum. 2006;35:208-210. [PMID: 16461067 DOI: 10.1016/j.semarthrit.2005.09.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 2021;51:736-47. [PMID: 33871726 DOI: 10.1007/s00247-020-04896-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Pao VY, Chang S, Shoback DM, Bikle DD. Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review. J Bone Miner Res 2009;24:1135-9. [PMID: 19113910 DOI: 10.1359/jbmr.081261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
3 Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-93. [PMID: 18220317 DOI: 10.1002/path.2311] [Cited by in Crossref: 98] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
4 Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. European Journal of Radiology 2008;66:187-90. [DOI: 10.1016/j.ejrad.2008.01.032] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
5 Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190:1060-8. [PMID: 18356456 DOI: 10.2214/AJR.07.2822] [Cited by in Crossref: 112] [Cited by in F6Publishing: 23] [Article Influence: 8.6] [Reference Citation Analysis]
6 Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR Am J Neuroradiol 2016;37:1192-8. [PMID: 26659341 DOI: 10.3174/ajnr.A4615] [Cited by in Crossref: 218] [Cited by in F6Publishing: 62] [Article Influence: 36.3] [Reference Citation Analysis]
7 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
8 Ramalho M, Ramalho J, Burke LM, Semelka RC. Gadolinium Retention and Toxicity—An Update. Advances in Chronic Kidney Disease 2017;24:138-46. [DOI: 10.1053/j.ackd.2017.03.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
9 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
10 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 25] [Article Influence: 11.8] [Reference Citation Analysis]
11 Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Investigative Radiology 2007;42:139-45. [DOI: 10.1097/01.rli.0000253505.88945.d5] [Cited by in Crossref: 178] [Cited by in F6Publishing: 135] [Article Influence: 12.7] [Reference Citation Analysis]
12 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
13 Provenzale JM. Nephrogenic Systemic Fibrosis: Some Considerations on the Debate Regarding Its Cause. American Journal of Roentgenology 2008;191:1867-9. [DOI: 10.2214/ajr.08.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned. American Journal of Roentgenology 2007;188:586-92. [DOI: 10.2214/ajr.06.1094] [Cited by in Crossref: 463] [Cited by in F6Publishing: 66] [Article Influence: 33.1] [Reference Citation Analysis]
15 Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82-8. [PMID: 22833806 DOI: 10.1093/ckj/sfr172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
16 Caccetta T, Chan JJ. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium: Nephrogenic systemic fibrosis. Australasian Journal of Dermatology 2008;49:48-51. [DOI: 10.1111/j.1440-0960.2007.00426.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
17 Nortier JL, del Marmol V. Nephrogenic systemic fibrosis the need for a multidisciplinary approach. Nephrology Dialysis Transplantation 2007;22:3097-101. [DOI: 10.1093/ndt/gfm430] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol. 2014;44:173-180. [PMID: 24057195 DOI: 10.1007/s00247-013-2795-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
19 Semelka RC, Ramalho J, Vakharia A, Alobaidy M, Burke LM, Jay M, Ramalho M. Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magnetic Resonance Imaging 2016;34:1383-90. [DOI: 10.1016/j.mri.2016.07.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 53] [Article Influence: 16.4] [Reference Citation Analysis]
20 Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med 2012;27:1697-703. [PMID: 22692632 DOI: 10.1007/s11606-012-2098-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
21 Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007;2:199-205. [PMID: 17712863 DOI: 10.1002/cmmi.146] [Cited by in Crossref: 142] [Cited by in F6Publishing: 107] [Article Influence: 10.1] [Reference Citation Analysis]
22 Boyd AS, Sanyal S, Abraham JL. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? J Am Acad Dermatol 2010;62:337-42. [PMID: 19939504 DOI: 10.1016/j.jaad.2009.04.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Kurtkoti J, Snow T, Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 2008;13:235-41. [PMID: 18221255 DOI: 10.1111/j.1440-1797.2007.00912.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
24 Plamondon I, Samson C, Watters AK, Bégin LR, Côté J, Déziel C, Quérin S. La fibrose systémique néphrogénique: nouveau coup dur pour les insuffisants rénaux. Néphrologie & Thérapeutique 2007;3:152-6. [DOI: 10.1016/j.nephro.2007.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
25 Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362. [PMID: 16885403 DOI: 10.1681/asn.2006060601] [Cited by in Crossref: 988] [Cited by in F6Publishing: 217] [Article Influence: 65.9] [Reference Citation Analysis]
26 Prasad SR, Jagirdar J. Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy: A Primer for Radiologists. Journal of Computer Assisted Tomography 2008;32:1-3. [DOI: 10.1097/rct.0b013e31805d08ee] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
27 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
28 Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: An update. Curr Rheumatol Rep 2006;8:151-7. [DOI: 10.1007/s11926-006-0056-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
29 Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3:968-75. [PMID: 18385397 DOI: 10.2215/CJN.00100108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
30 Schieren G, Tokmak F, Lefringhausen L, van Bracht M, Perings C, Willers R, Günsel A, Kemper F, Wiesmüller GA, Rump LC. C-Reactive Protein Levels and Clinical Symptoms Following Gadolinium Administration in Hemodialysis Patients. American Journal of Kidney Diseases 2008;51:976-86. [DOI: 10.1053/j.ajkd.2008.02.299] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
31 Wiedemeyer K, Kutzner H, Abraham JL, Thakral C, Carlson JA, Tran TA, Hausser I, Hartschuh W. The Evolution of Osseous Metaplasia in Localized Cutaneous Nephrogenic Systemic Fibrosis: A Case Report. The American Journal of Dermatopathology 2009;31:674-81. [DOI: 10.1097/dad.0b013e3181a1fb55] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
32 Moreno-romero J, Segura S, Mascaró J, Cowper S, Julià M, Poch E, Botey A, Herrero C. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007;157:783-7. [DOI: 10.1111/j.1365-2133.2007.08067.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
33 Heymann WR. Nephrogenic systemic fibrosis—The beginning of the end? Journal of the American Academy of Dermatology 2007;57:171-2. [DOI: 10.1016/j.jaad.2007.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA. Nephrogenic systemic fibrosis: A clinicopathologic study of six cases. Journal of the American Academy of Dermatology 2007;57:105-11. [DOI: 10.1016/j.jaad.2007.02.021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
36 Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. Appl Immunohistochem Mol Morphol 2010;18:448-52. [PMID: 20485155 DOI: 10.1097/PAI.0b013e3181de372e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
37 Roditi G, Maki JH, Oliveira G, Michaely HJ. Renovascular imaging in the NSF Era. J Magn Reson Imaging. 2009;30:1323-1334. [PMID: 19937926 DOI: 10.1002/jmri.21977] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
38 Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology 2011;64:91-6. [DOI: 10.1016/j.jaad.2009.12.044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
39 Cowper SE. Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium. Advances in Dermatology 2007;23:131-54. [DOI: 10.1016/j.yadr.2007.07.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
40 Garcia J, Liu SZ, Louie AY. Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus. Philos Trans A Math Phys Eng Sci 2017;375:20170180. [PMID: 29038383 DOI: 10.1098/rsta.2017.0180] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
41 Manger B. Nephrogene systemische Fibrose: Medizinische Detektivarbeit im 21. Jahrhundert. Z Rheumatol 2007;66:533-5. [DOI: 10.1007/s00393-007-0186-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
42 High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21-26. [PMID: 17097388 DOI: 10.1016/j.jaad.2006.10.047] [Cited by in Crossref: 361] [Cited by in F6Publishing: 267] [Article Influence: 24.1] [Reference Citation Analysis]
43 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
44 Panesar M, Boateng F, Patel SS, Masood SF, Mahajan P, Patel N, Murray B. Transmetallation and gadolinium: Do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?: Gadopentetate and transmetallation. Hemodialysis International 2010;14:289-94. [DOI: 10.1111/j.1542-4758.2010.00456.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
45 Semelka RC, Commander CW, Jay M, Burke LM, Ramalho M. Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases. Invest Radiol 2016;51:661-5. [DOI: 10.1097/rli.0000000000000318] [Cited by in Crossref: 52] [Cited by in F6Publishing: 14] [Article Influence: 10.4] [Reference Citation Analysis]
46 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
47 Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30. [PMID: 17109993 DOI: 10.1016/j.jaad.2006.10.048] [Cited by in Crossref: 294] [Cited by in F6Publishing: 228] [Article Influence: 19.6] [Reference Citation Analysis]